202 related articles for article (PubMed ID: 12393385)
1. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Shan J; Rios MB; Cortes J
Blood; 2003 Jan; 101(2):473-5. PubMed ID: 12393385
[TBL] [Abstract][Full Text] [Related]
2. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
3. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Cortes J; Giles F; O'Brien S; Thomas D; Garcia-Manero G; Rios MB; Faderl S; Verstovsek S; Ferrajoli A; Freireich EJ; Talpaz M; Kantarjian H
Blood; 2003 Jul; 102(1):83-6. PubMed ID: 12637317
[TBL] [Abstract][Full Text] [Related]
4. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Kantarjian HM; Cortes JE; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Jeha S; Rios MB; Letvak L; Bochinski K; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(1):97-100. PubMed ID: 12393600
[TBL] [Abstract][Full Text] [Related]
6. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
8. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL; Wolf D; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Oucheva R; Ulmer H; Kwakkelstein M; Rancati F; Gastl G
Haematologica; 2010 Jun; 95(6):908-13. PubMed ID: 20145273
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
Sohn SK; Moon JH; Cho YY; Chae YS; Kim JG; Lee KS; Hong SP; Kim SO
Leuk Lymphoma; 2007 Aug; 48(8):1659-61. PubMed ID: 17701605
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L; Voglová J
Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
13. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
[TBL] [Abstract][Full Text] [Related]
14. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Marin D; Goldman JM; Olavarria E; Apperley JF
Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
[No Abstract] [Full Text] [Related]
15. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
16. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
[TBL] [Abstract][Full Text] [Related]
17. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Faber E; Nausová J; Jarosová M; Egorin MJ; Holzerová M; Rozmanová S; Maresová I; Divoký V; Indrák K
Leuk Lymphoma; 2006 Jun; 47(6):1082-90. PubMed ID: 16840200
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
19. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
